Search Tag: Rapiblyk

2025 21 Jul

Rapiblyk™ now available for order by healthcare providers in the U.S. Cencora   AOP Orphan Pharmaceuticals GmbH (AOP Health) today announced that Rapiblyk™ (landiolol), an ultra-short-acting, selective beta-1 adrenergic receptor blocker, is now commercially available in the United States and can be ordered through Cencora. This follows the U1Read more